the door is open wide. Multiple blood cancers being tested now - very likely multiple phII studies or single multi-arm study doing K stand-alone multi-dose arms and K-combo arms (my favorite kind of study - if you can't tell!). So - it K efficacious in multiple blood cancers - it will become go-to. And if it piggybacks as well - usage will be broad in a literal sense. Ctix is employing a broad spectrum approach to hematologic oncology. It's a business tactic - so far perfectly executed. Pcyc, with such awesome potential to effect this whole family of blood CA - failed to do multi-arm testing. So - even though they'll beat ctix in getting treatment labels for a couple of the leukemias - ctix might swoop in in a couple of years with indications for an entire family of diverse hematolgic cancers.